Active repression by RARγ signaling is required for vertebrate axial elongation

Amanda Janesick1, Tuyen T. L. Nguyen1, Ken-ichi Aisaki2, Katsuhide Igarashi2, Satoshi Kitajima2, Roshantha A. S. Chandraratna3, Jun Kanno2 and Bruce Blumberg1,4,∗

ABSTRACT
Retinoic acid receptor gamma 2 (RARγ2) is the major RAR isoform expressed throughout the caudal axial progenitor domain in vertebrates. During a microarray screen to identify RAR targets, we identified a subset of genes that pattern caudal structures or promote axial elongation and are upregulated by increased RAR-mediated repression. Previous studies have suggested that RAR is present in the caudal domain, but is quiescent until its activation in late stage embryos terminates axial elongation. By contrast, we show here that RARγ2 is engaged in all stages of axial elongation, not solely as a terminator of axial growth. In the absence of RA, RARγ2 represses transcriptional activity in vivo and maintains the pool of caudal progenitor cells and presomitic mesoderm. In the presence of RA, RARγ2 serves as an activator, facilitating somite differentiation. Treatment with an RARγ-selective inverse agonist (NRX205099) or overexpression of dominant-negative RARγ increases the expression of posterior Hox genes and that of marker genes for presomitic mesoderm and the chordoneural hinge. Conversely, when RAR-mediated repression is reduced by overexpressing a dominant-negative co-repressor (c-SMRT), a constitutively active RAR (VP16-RARγ2), or by treatment with an RARγ-selective agonist (NRX204647), expression of caudal genes is diminished and extension of the body axis is prematurely terminated. Hence, gene repression mediated by the unliganded RARγ2-co-repressor complex constitutes a novel mechanism to regulate and facilitate the correct expression levels and spatial restriction of key genes that maintain the caudal progenitor pool during axial elongation in Xenopus embryos.

KEY WORDS: Active repression, Axial elongation, Chordoneural hinge, Posterior Hox, Presomitic mesoderm, Retinoic acid receptor

INTRODUCTION
Repression mediated through unliganded retinoic acid receptors (RARs) is an important yet understudied function exhibited by nuclear receptors (reviewed by Weston et al., 2003). Although RA plays a major role in patterning the hindbrain, retina, placodes and somites, its absence is crucial for the development of structures found at the head and tail of the embryo. RARs exhibit basal repression in the absence of ligand, binding constitutively to their targets, recruiting co-repressors, and actively repressing the basal transcriptional machinery (Chen and Evans, 1995). When ligand is present, co-repressors are replaced by co-activators and target genes are transcribed (Chakravarti et al., 1996).

We previously demonstrated that repression mediated through unliganded RARs was important for anterior neural patterning, establishing a novel role for RAR as a repressor in vivo (Koida et al., 2001). Overexpression of a dominant-negative RARα expanded anterior and midbrain markers caudally and shifted somitomeres rostrally (Blumberg et al., 1997; Moreno and Kintner, 2004). Exogenous RA, constitutively active RARα or derepression of RARα produced the opposite effect: severe anterior truncations, diminished anterior markers, and anteriorly shifted midbrain and hindbrain markers. Stabilization of co-repressors resulted in enhanced anterior neural structures and posteriorly shifted mid/hindbrain markers (Koida et al., 2001).

Axial elongation requires continual replenishing of bipotential caudal progenitor cells (maintained by Wnt and FGF signaling, but inhibited by RA) that give rise to notochord, neural tube and somites (Cambray and Wilson, 2002; Davis and Kirschner, 2000). The most stem-like cells are located in the chordoneural hinge (CNH), where the posterior neural plate overlies the caudal notochord (Beck and Slack, 1998). Cells from the CNH contribute to presomitic mesoderm (PSM), which supplies committed somitic precursor cells to the rostral determination wavefront (reviewed by Dequen and Pourquié, 2008). PSM is initially homogenous and unorganized (expressing Mesogenin1 (Msn1) and Tbx6), then becomes patterned into somitomeres marked by Thyascine2 (Thy2) and Rippy2 (reviewed by Dahmann et al., 2011). Epithelialization of presomitic domains results in mature somites (Nakaya et al., 2004).

RA is well known to function in the trunk, where it promotes differentiation of PSM into somitomeres (Moreno and Kintner, 2004). By contrast, RA is actively metabolized and cleared by CYP26A1 in the caudal region (Fuji et al., 1997). Treatment with RA leads to loss of posterior structures (Sive et al., 1990; Cyp26a1−/− mice exhibit posterior truncations and homeotic vertebral transformations (Abu-Abed et al., 2001; Sakai et al., 2001). Exposing embryos to RA inhibits proliferation of axial progenitor cells in CNH and PSM, leading to axial truncation from premature exhaustion of the progenitor pool (Gomez and Pourquié, 2009). Therefore, RA is normally excluded from unsegmented mesenchyme in PSM and the CNH. RARγ is expressed at high levels throughout the entire caudal region, including CNH and PSM (Mollard et al., 2000; Pfeffer and De Robertis, 1994), yet, based on Cyp26a1 expression, RA is absent (de Roos et al., 1999). The physiological significance of RARγ expression in the embryonic posterior is uncertain. RARγ might function to terminate the body axis at late stages by inducing apoptosis (Olivera-Martinez et al., 2012), but that model would not explain the strong expression of RARγ observed at neurula, continuing through tailbud stages, despite the apparent absence of RA.
RARγ2 skirts the posterior edge of the determination wavefront and is co-expressed with PSM, CNH and posterior Hox markers. We hypothesized that RARγ2 serves a dual function: as an activator in somite differentiation but a repressor in the maintenance of PSM and the caudal progenitor pool. Loss of RARγ2 severely shortens the embryo body axis and inhibits somitogenesis. Loss of RARγ2 expands the anterior border of PSM expression near the wavefront (where activation is lost), but diminishes the expression domain of caudal PSM and posterior Hox genes (where repression is lost). Increasing RAR-mediated repression expands the expression of posterior Hox, PSM and CNH markers, creating smaller somitomere domains via an indirect, ‘repressing a repressor’ mechanism. Relief of repression results in a truncated body axis with decreased PSM and CNH markers. Axial extension and segmentation in vertebrates relies on the maintenance of unsegmented PSM mesenchyme and replenishing of caudal progenitor cells. Our data show that RARγ2 plays a crucial role in this process, repressing target genes to maintain PSM and caudal progenitors in the absence of RA, while activating others to promote somitogenesis in the presence of RA.

RESULTS

Posterior Hox, PSM and CNH genes are upregulated by RAR inverse agonist

We showed previously that active repression of RAR target genes by unliganded RAR is required for head formation (Koide et al., 2001). Treatment with the pan-RAR inverse agonist AGN193109 increased the expression of genes involved in patterning anterior neural structures, whereas treatment with pan-RAR agonist TTNPB decreased the expression of anterior marker and cement gland-specific genes (Koide et al., 2001), revealing a set of genes specifically upregulated/downregulated by TTNPB (Arima et al., 2005). Validation studies identified a subset upregulated by AGN193109. We hypothesized that active repression by unliganded RARs is biologically important and designed an experiment to identify genes upregulated or downregulated by modulating repression. Percellome analysis (Kanno et al., 2006) quantified the copy number per embryo of all genes represented on Affymetrix Xenopus microarray v1.0. Among these we identified a collection of genes linked to the maintenance of caudal axial progenitors that were downregulated by TTNPB and upregulated by AGN193109 (Table 1). RAR-mediated repression upregulates the steady-state expression of posterior Hox paralogs 9-13 and genes found in both unsegmented PSM and CNH.

Thus, we hypothesized that RAR is a repressor required for axial elongation.

Xenopus RARs repress basal transcription in the absence of ligand

The ability of unliganded RARs to behave as repressors is well documented, although not all human receptor subtypes can recruit co-repressors (e.g. SMRT) in the absence of ligand (Wong and Privalsky, 1998). We tested the ability of Xenopus RAR (xRAR) subtypes to repress basal activity of a luciferase-dependent reporter using the GAL4-RAR system (supplementary material Fig. S1D-F) (Blumberg et al., 1996). Xenopus RARα, RARβ and RARγ suppressed basal activity in vitro and in vivo (supplementary material Fig. S1A,C), whereas human RARβ and RARγ did not (supplementary material Fig. S1B). Thus, xRARs can function as repressors in the absence of ligand.

RARγ2 is expressed in the PSM and CNH but is mostly absent from the trunk

Whole-mount in situ hybridization (WISH) revealed that RARγ2 is the predominant isoform expressed in the Xenopus embryonic posterior (supplementary material Fig. S2A). In late neurula and early tailbud stage embryos, RARγ2 is strongly expressed in the anterior and posterior, but almost undetectable in the trunk. RARγ2 expression later becomes pronounced in the tail and head, particularly in hyoid, branchial and mandibular neural crest. RARγ1 is expressed similarly. QPCR analysis revealed that RARγ2 is 1000- to 4000-fold more abundant than RARγ1 at stages 10-22, and 100- to 400-fold more abundant at all other stages analyzed (supplementary material Fig. S2B). Subsequent experiments utilized RARγ2-selective reagents. We conclude that RARγ2 is the predominant isoform expressed in the posterior region of embryos.

RARγ2 is expressed where RA is probably absent (owing to CYP26A1 expression). Key posterior genes were upregulated by AGN193109. We hypothesized that RARγ2 posterior to the wavefront is a repressor, maintaining unsegmented PSM and the progenitor cell pool required for axial elongation. We used double WISH to compare the expression of RARγ2 with that of Hoxc10, an important member of the Abd-B Hox gene family promoting caudal development over thorax (Lamka et al., 1992). RARγ2 expression completely overlaps caudal Hoxc10 expression (Fig. 1E,H) but not the anteriormost neural or lateral plate expression of Hoxc10 (Fig. 1E,H). These data position

<table>
<thead>
<tr>
<th>Unigene</th>
<th>109 (fold)</th>
<th>P</th>
<th>TTN (fold)</th>
<th>P</th>
<th>Symbol</th>
<th>Gene name</th>
<th>Cat</th>
</tr>
</thead>
<tbody>
<tr>
<td>XI.72193</td>
<td>3.57</td>
<td>2.11×10−3</td>
<td>0.19</td>
<td>5.77×10−4</td>
<td>Hoxc13</td>
<td>Homeobox C13</td>
<td>PP</td>
</tr>
<tr>
<td>XI.266</td>
<td>3.47</td>
<td>4.26×10−3</td>
<td>0.12</td>
<td>2.26×10−4</td>
<td>Hoxa11</td>
<td>Homeobox A11</td>
<td>PP</td>
</tr>
<tr>
<td>XI.21684</td>
<td>3.15</td>
<td>2.03×10−3</td>
<td>0.22</td>
<td>2.68×10−4</td>
<td>Hoxa6</td>
<td>Homeobox A6</td>
<td>PP</td>
</tr>
<tr>
<td>XI.72292</td>
<td>3.02</td>
<td>7.32×10−3</td>
<td>0.16</td>
<td>1.62×10−4</td>
<td>Hoxd9</td>
<td>Homeobox D9</td>
<td>PP</td>
</tr>
<tr>
<td>XI.9560</td>
<td>2.73</td>
<td>9.74×10−4</td>
<td>0.40</td>
<td>5.98×10−3</td>
<td>Hoxa9</td>
<td>Homeobox A9</td>
<td>PP</td>
</tr>
<tr>
<td>XI.12067</td>
<td>2.80</td>
<td>8.05×10−3</td>
<td>0.18</td>
<td>2.51×10−5</td>
<td>Esr2</td>
<td>Enhancer of Split related 2</td>
<td>PSM</td>
</tr>
<tr>
<td>XI.29033</td>
<td>2.79</td>
<td>9.31×10−4</td>
<td>0.26</td>
<td>1.62×10−5</td>
<td>Esr9</td>
<td>Enhancer of Split related 9</td>
<td>PSM</td>
</tr>
<tr>
<td>XI.78953</td>
<td>2.90</td>
<td>4.29×10−4</td>
<td>0.37</td>
<td>2.68×10−3</td>
<td>Tbx6</td>
<td>T-box gene Tbx6</td>
<td>PSM</td>
</tr>
<tr>
<td>XI.483</td>
<td>2.53</td>
<td>4.18×10−3</td>
<td>0.17</td>
<td>3.36×10−4</td>
<td>Msnog1</td>
<td>Megosin</td>
<td>PSM</td>
</tr>
<tr>
<td>XI.14524</td>
<td>2.32</td>
<td>2.76×10−2</td>
<td>0.42</td>
<td>1.46×10−3</td>
<td>Esr5</td>
<td>Enhancer of Split related 5</td>
<td>PSM</td>
</tr>
<tr>
<td>XI.933</td>
<td>2.49</td>
<td>4.46×10−2</td>
<td>0.40</td>
<td>2.73×10−2</td>
<td>xBrα3</td>
<td>T2, Brachyury homolog</td>
<td>CNH</td>
</tr>
<tr>
<td>XI.1066</td>
<td>2.44</td>
<td>4.31×10−2</td>
<td>0.34</td>
<td>2.09×10−3</td>
<td>xNot</td>
<td>Notochord homebox</td>
<td>CNH</td>
</tr>
<tr>
<td>XI.457</td>
<td>3.10</td>
<td>1.37×10−3</td>
<td>0.02</td>
<td>2.81×10−7</td>
<td>Derriere</td>
<td>Growth differentiation factor 3</td>
<td>NC</td>
</tr>
<tr>
<td>XI.16206</td>
<td>2.43</td>
<td>7.64×10−3</td>
<td>0.27</td>
<td>2.35×10−6</td>
<td>Pnp</td>
<td>Purine nucleoside phosphorylase</td>
<td>NC</td>
</tr>
</tbody>
</table>
Fig. 1. Double WISH reveals the spatial relationship between Rary2 and posterior Hox, PSM and CNH genes. (A-M) Rary2 is stained with BM Purple and the other genes are stained with Fast Red. Rary2 is caudal to Myod and Tbx6 (A-D), but synexpressed with Msgn1 (F,G) in neurula stage Xenopus embryos. (E,H) Rary2 is synexpressed with the caudal domain (CD) of Hoxc10 but not with neural tube (NT) or lateral plate mesoderm (LPM) of Hoxc10 in tailbud stage embryos. Rary2 overlaps with S–III domains of Ripply2 (L,J) and Thyl2 (L,M) expression, but not with more anterior somitomeres (S–II, S–I, S0). (K) Rary2 overlaps with xNot expression in neurula stage embryos. Dorsal and lateral views shown with anterior to the left, except in K (caudal view with dorsal at top).

Rary2 as a potential regulator of posterior Hox genes and the caudal body plan.

We next defined the anterior limit of Rary2 expression relative to the determination wavefront. Myod is a general muscle marker abutting and partially overlapping Rary2 expression (Fig. 1A,B). Thyl2 and Ripply2 mark somitomeres, which are prepatterned PSM domains containing non-epithelialized, immature somites (Tam et al., 2000). Thyl2 and Ripply2 are only expressed in newly forming somitomeres and are assigned negative Roman numerals (S–I, S–II, etc.) versus mature somites (SI, SII, etc.) (Pourquie and Tam, 2001). Msgn1 (Buchberger et al., 2000) is expressed caudal to Thyl2 and Ripply2, marking non-patterned PSM-containing cells committed to the somitic fate (Nowotschin et al., 2012). Tbx6 is also expressed in PSM, but unlike Msgn1 its expression domain overlaps with somitomeres (Hitachi et al., 2008). Rary2 and Msgn1 are synexpressed at neurula (Fig. 1F,G) and tailbud (supplementary material Fig. S3) stages; Tbx6 expression overlaps Rary2 but extends rostrally beyond the Rary2 domain (Fig. 1C,D; supplementary material Fig. S3). Anterior expression of Rary2 mRNA ends at an RA-responsive region (supplementary material Fig. S4), coinciding with the most posterior somitomere domain (S–III) of Thyl2 or Ripply2 (Fig. 11–M), thus skirting the posterior edge of the wavefront.

xNot, a notch chord marker that regulates trunk and tail development, is concentrated in the extreme posterior notochord and floor plate by late neurula (von Dassow et al., 1993) and is often employed as a CNH marker in Xenopus (Beck and Slack, 1998) to reveal the location of bipotential stem cells (Cambray and Wilson, 2007; Takemoto et al., 2011). xNot is co-expressed with Rary2 (Fig. 1K), agreeing with data suggesting that Rary2 is present in CNH (Pfeffer and De Robertis, 1994). The double WISH data are consistent with Rary2 functioning as an activator near where RA is present at the wavefront, yet as a repressor where it coincides with Msgn1, xNot and Cyp26a1.

RARγ-selective chemicals modulate activation or repression by RARγ

To separate the effects of RARγ in the posterior from RARα in the trunk, we characterized RARγ-selective agonist NRX204647 (4647) (Shimono et al., 2011; Thacker et al., 2000) and RARγ-selective inverse agonist NRX205099 (5099) (Tsang et al., 2003) in Xenopus embryos. Like AGN193109, 5099 is an inverse agonist, reducing RARγ signaling activity below basal levels by stabilizing the co-repressor complex bound to RARγ. Embryos treated with 1 μM agonist 4647 become primarily trunk (no head or tail structure), while 0.1 μM perturbs axial elongation (supplementary material Fig. S5), producing anterior truncations characteristic of RAR activators (Sive et al., 1990). Inverse agonist 5099 at 1 μM delayed development, producing enlarged heads and shortened trunks; half the dose elicited similar but weaker phenotypes, with effects absent at 0.1 μM (supplementary material Fig. S5). Treating neurula embryos significantly reduced severity but did not eliminate the phenotype (supplementary material Fig. S5).

To test the effects of these chemicals in vivo without interference from endogenous RARs, we mutated the DNA-binding specificity of a full-length RAR, RARGCGKKG–GSCCKV. The mutant receptor recognizes a mutant TK-luc reporter, (RXRE1/2–GRE1/2)×4 TK-luc, to which endogenous RARs do not bind (Klein et al., 1996). In transient transfection assays, 4647 selectively activated RARγ at doses below 0.1 μM (supplementary material Fig. S6A). Similarly, 5099 selectively antagonized 10 nM 9-cis RA activation of RARγ below 0.1 μM (supplementary material Fig. S6B). We conclude that 4647 and 5099 behave as subtype-selective ligands to activate or repress RARγ.

RARγ-selective chemicals affect posterior Hox genes, PSM and somitomeres

We hypothesized that 4647 treatment of embryos would decrease posterior Hox gene expression and markers of PSM, whereas 5099 would produce the opposite effect. Microarray analysis (Table 1) revealed that Hoxc13 and Hoxc10 expression was upregulated by inverse agonist AGN193109 and downregulated by agonist TTNPB. We infer that increased expression of Hoxc13 and Hoxc10 results from RAR repressing the expression of a repressor of their expression. The expression pattern of Hoxc13 (supplementary material Fig. S7) was not previously characterized.

We began soaking embryos in RARγ-selective doses of 4647, 5099 or vehicle control after gastrulation (stage 12.5) to focus on axial elongation. Treatment with 10 nM 4647 resulted in diminished caudal structures at stage 40 (supplementary material Fig. S5), reducing expression domains of Hoxc10, Hoxd10 and Hoxc13 (Fig. 2A-C). Conversely, treatment with 0.5 μM 5099 expanded their neural and lateral domains (Fig. 2A-C). To determine short-term effects of chemical treatments, we soaked embryos for 1 h at various stages and evaluated Hoxc10 expression (supplementary material Fig. S8) and that of Tbx6 (not shown) at stage 22. Repression by 5099 is required at early neurula, whereas activation by 4647 is required at mid- and late neurula stages for expected expansion and reduction, respectively, of Hoxc10 expression (supplementary material Fig. S8). Higher, non-receptor-selective doses exacerbated effects on posterior Hox genes (supplementary material Fig. S9), suggesting that Rary2 is the primary mediator. Hoxc10 nearly abuts Krox20, demonstrating trunk shortening in 5099-treated embryos (supplementary material Fig. S9G,H). High
doses of 4647 create embryos lacking anterior and posterior structures, as indicated by the absence of mid/hindbrain markers En2 and Krox20 and of posterior gene Hoxc10 (supplementary material Fig. S9C-F).

Msgn1 and Tbx6 were upregulated by inverse agonist and downregulated by agonist in the microarray analysis (Table 1). Msgn1 and Tbx6 domains were reduced at tailbud stages by post-gastrulation treatment of embryos with 4647, whereas expression was expanded in embryos treated with inverse agonist 5099 (Fig. 2D,E). However, in neurula stage embryos, 4647 reduced Msgn1 expression while Tbx6 expression was expanded (Fig. 3E,F,O,P). Expression of Tbx6 and Msgn1 was expanded by 5099 (Fig. 3J,Q,R), an effect that was more pronounced at higher doses (supplementary material Fig. S10I,J,Q,R). Somitomere markers Thyl2 and Ripply2 showed thicker domains; S–III expanded to the posteriormost edge of the embryo where somites are not found in controls (Fig. 3G,H). At non-receptor-selective doses, 4647 exacerbated the phenotypes of embryos treated with inverse agonist 5099 (Fig. 2D,E). Expansion of Msgn1 and Tbx6 anteriorly along the midline (Fig. 3K,L) showed relative to control vehicle. Embryos shown in lateral or dorsal view at tailbud stage, anterior to left.

**Relief of repression reduces domains of posterior Hox and PSM markers**

Treatment with 4647 activates RARγ and removes repressors from RARγ targets, creating posterior truncations. We hypothesized that loss of RARγ2 would phenocopy 4647 treatment once RARγ2-mediated repression was lost. We designed AUG MOs to capture both pseudoalleles of RARγ2. Knockdown of RARγ2/1.2 resulted in loss of expression of Hoxc10, Hoxd10, Hoxa11 and Hoxc13 expression expanded by 5099 treatment (17/17 embryos). (F) Tbx6 expression expanded by 4647 treatment (22/22). (G-H) Somitomere domains of Thyl2 and Ripply2 (17/17) are thicker and posteriorly expanded. (L) Msgn1 (17/17) and Tbx6 (13/13) expression expanded by 5099 treatment. (K,L) Somitomere domains of Thyl2 (15/17) and Ripply2 (26/26) are fewer and thinner. Embryos are shown in dorsal view at neurula stage, anterior to left. (M-R) Caudal Views of Msgn1 and Tbx6.

When the dominant-negative co-repressor c-SMRT is overexpressed, it binds RAR and blocks recruitment of co-repressors (Chen et al., 1996). We identified several c-SMRT isofoms from Xenopus, selecting that most similar to human c-SMRT that we used previously. Microinjection of Xenopus laevis (XI) c-smrt mRNA relieved...
repression by GAL4-xRARγ in whole embryos (supplementary material Fig. S14). This effect was potentiated by addition of 1 µM TTPNB (supplementary material Fig. S14). Overexpression of XI c-smrt mRNA caused significant reductions in the neural and lateral domains of Hoxc10 and Hoxd10 (Fig. 6B,D). XI c-smrt also reduced Hoxc13, Tbx6, Msgn1 and xNot (Fig. 6F,H,H’,J’,J,L). Similar to Rarγ2 MO, moderate truncation of injected axes was observed in 70% of embryos, but the midline, rostral shifting of Tbx6 and Msgn1 (as in Rarγ2 MO embryos) was minimal. We conclude that XI c-SMRT relieves repression of Rarγ2, causing loss of progenitor and PSM cells and posterior Hox gene expression.

Another method for relieving repression is overexpression of constitutively active VP16-RARγ2 (RARγ2 fused to the VP16 activation domain). Microinjection of VP16-RARγ2 mRNA led to a truncated axis on the injected side in 100% of embryos and loss of Hoxc10, Hoxd10, Msgn1 and Tbx6 expression (Fig. 7). These embryos were less curved than Rarγ2 MO-injected or c-smrt- injected embryos, but rostral expansion of neural/midline and lateral domains was consistently observed, similar to Rarγ2 MO embryos.

**Increased repression expands posterior Hox and PSM markers**

Treatment with 4647 or microinjection of c-smrt or VP16-RARγ2 mRNA relieved repression by RARγ, increasing RAR signaling, decreasing posterior Hox and PSM markers. Decreasing RAR signaling should produce the opposite effect. We microinjected mRNA overexpressing the RA catabolic enzyme CYP26A1 and observed rostral shifts in the lateral and neural expression domains of Hoxc10 and Hoxd10 (supplementary material Fig. S15). Microinjection of dominant-negative (DN)-RARγ2 increased the expression of Msgn1 and Tbx6 in both lateral and paraxial domains, and shifted xNot expression rostrally (Fig. 8B,D,F). DN-RARγ2 phenocopied the effects of Cyp26a1 mRNA (Moreno and Kintner, 2004) on somitomere markers Thy2 and Ripply2: rostral shifting and knockdown of somitomere expression was the phenotype that we observed (Fig. 8H,J,K).

Microinjection of Rarγ2 MO alone resulted in knockdown of Hoxc10 and axial truncation (Fig. 9A,B,E). We hypothesized that this phenotype was due to loss of repression, reasoning that the phenotype should be rescued with DN-RARγ2. Axial defects and lateral knockdown of Hoxc10 expression were partially recovered with DN-Rarγ2 mRNA (Fig. 9C,D,E). The neural domain of Hoxc10 expression was rescued in nearly all embryos and a rostral shift often observed. We conclude that increasing repression with DN-RARγ2 or overexpressing CYP26A1 (removing ligand) promotes caudal gene expression, similar to chemical treatment with 5099. Moreover, loss of caudal structures and gene expression due to Rarγ2 MO are rescued by restoring repression with DN-RARγ2.

**DISCUSSION**

**RARγ repression in caudal development**

Most studies consider only one aspect of RAR signaling, namely its role as a ligand-activated transcription factor promoting the expression of target genes. In developmental biology, RA signaling has been studied extensively for its ability to promote differentiation and establish boundaries in somitogenesis, neurogenesis and rhombomere segmentation (reviewed by Rhinn and Dolle, 2012). Liganded RAR has been predicted to function passively in the caudal region until required to facilitate body axis cessation (Olivena-Martinez et al., 2012), when somitogenesis is nearing completion because the determination wavefront, moving the RA source caudally, has exhausted the progenitor cell pool (Gomez and Pourquie, 2009). Here, liganded RARγ would function as an activator promoting apoptosis (Shum et al., 1999) at terminal tailbud stage. However, this does not address why RARγ2 would be highly expressed where RA is...
whether this repression is physiologically relevant in caudal basal transcriptional activity in the absence of RA and examined PSM and stem-like CNH.

RAR repression in the maintenance of cells in both unsegmented

2012; Yabe and Takada, 2012). Our results support a novel role of populations of cells:

suggests the existence of a negative-feedback loop between these two downregulated by increasing RAR activation. Current literature markers were upregulated by enhancing RAR repression and (12/14) and (F,H,J) c-smrt overexpression shortens the axis on injected side in 70% of embryos. (B) c-smrt mRNA results in lateral knockdown (13/23 embryos), neural knockdown (7/23) or neural rostral shift (7/23) in Hoxc10 expression. (D) c-smrt mRNA produces neural and lateral knockdown (15/19) or lateral knockdown alone (4/19) of Hoxd10 expression. (F,H,J) c-smrt mRNA knocks down expression of Hoxc13 (14/18), Msgn1 (12/14) and Tbx6 (15/15). Tailbud embryos shown with anterior to left. (H,J) Caudal views of H and J. (L) c-smrt mRNA knocks down xNot (12/15) expression in neurula stage embryos (caudal view, dorsal to top).

presumed absent due to CYP26A1 expression. Here we show that RARγ is engaged in all stages of caudal development, not solely as a terminator of the body axis. RARγ functions as an unliganded repressor required for the maintenance of the posterior PSM and progenitor cell population that allows axial elongation (Fig. 10). RARγ acts as a liganded activator in the anterior, segmented PSM to facilitate somite differentiation (Fig. 10). Repression mediated by the unliganded receptor co-repressor complex constitutes a novel mechanism by which posterior markers are upregulated during axial elongation in Xenopus embryos.

Our microarray results suggest that axial elongation is regulated by RAR-mediated repression. Enhancing repression with AGN193109 upregulated, and activation of RAR by TTNPB downregulated, many posterior Hox, PSM and CNH genes in neurula stage embryos. We identified AGN193109 upregulated genes expressed in PSM (Table 1) that are mostly absent from regions of somite maturation (Blewitt, 2009; Yoon et al., 2000). The CNH markers xBra3 and xNot were also upregulated by AGN193109, thus both PSM and CNH markers were upregulated by enhancing RAR repression and downregulated by increasing RAR activation. Current literature suggests the existence of a negative-feedback loop between these two populations of cells: Msgn1 is induced by Brachyury and Wnt8 in CNH but represses their expression to promote PSM fates (Fior et al., 2012; Yabe and Takada, 2012). Our results support a novel role of RAR repression in the maintenance of cells in both unsegmented PSM and stem-like CNH.

We showed that X. laevis RARα, RARβ and RARγ can repress basal transcriptional activity in the absence of RA and examined whether this repression is physiologically relevant in causal development. RAR2 is expressed in embryonic regions where it might actively repress genes involved in axial elongation. RARγ is synergized by the PSM marker Msgn1 and overlaps with Tbx6, Hoxc10, the S–III domains of Thy12 and Ripply2, and the CNH marker xNot. By contrast, RARγ is expressed at low levels in trunk (where Myod and Rara are expressed) and in the anterior, segmented PSM expression domains of Thy12 and Ripply2. Since absence of RA is required for the proliferation and/or survival of caudal PSM and CNH, the presence of RARγ in posterior tissue would be contradictory if it functioned as an activator. We infer that RARγ acts as a repressor throughout unsegmented PSM and CNH where RA is absent, but as an activator of somitomere markers near the differentiation wavefront where RARγ overlaps with S–II and where Ralh2 expression indicates the presence of RA. It remains unknown what repressors RARγ targets to indirectly upregulate caudal genes. One possibility is that RARγ represses Ripply2, which functions to repress Tbx6 (reviewed by Dahmann et al., 2011), as supported by the observation that increasing activation with 4647 expands Ripply2 posteriorly. Hence, RARγ would normally function in the posterior to repress Ripply2, therefore promoting expression of Tbx6.

RARγ repression promotes the maintenance of unsegmented PSM and CNH

Since high doses of 4647 result in embryos consisting largely of trunk, it is predictable that nearly the entire embryo differentiated into somitomeres (with thicker boundaries). At lower, RARγ-selective 4647 doses, somitomeres were shifted posteriorly and thickened. This phenotype, which is also seen with RA treatment or FGF inhibition by SU5402, was attributed to increased numbers of cells allocated to somitomeres and a decreased progenitor pool (Dubrulle et al., 2001; Moreno and Kintner, 2004). 5099 upregulates both Tbx6 and Msgn1, indicating that unsegmented PSM is expanded by increased RAR
repression. However, we note distinct differences in the effects of 4647 on Tbx6 versus Msgn1. Tbx6 is upregulated by 4647 at early stages but downregulated at later stages, as also observed for the T-box gene Tbx1 (Janesick et al., 2012). Unlike Msgn1, Tbx6 plays a dual role in the unsegmented PSM and the determination front where it controls the anteroposterior patterning of somitomeres via Ripply2 (Hitachi et al., 2008).

Msgn1 expression does not overlap somitomeres and functions to maintain unsegmented PSM by encouraging the differentiation of caudal stem cells. Loss of Msgn1 expression leads to smaller somitomeres owing to the accumulation of bipotential progenitor cells that have not received signals to commit to PSM fate (Fior et al., 2012; Yabe and Takada, 2012). Treatment with 4647 also leads to loss of Msgn1 and thus somitomeres should be smaller; however, they are larger. Despite such divergent early stage phenotypes, Msgn1−/− embryos (Yoon and Wold, 2000) and 4647 embryos both display fewer somites and reduced caudal structures at late stages. Caudal progenitors cannot be instructed to become somites in Msgn1−/− embryos. In 4647-treated embryos, the pool is expeditiously transformed into thickened somitomeres early, but the progenitor supply is exhausted before axial elongation is complete, reducing somitomere numbers. That 4647 can differentiate somitomeres at all without Msgn1 is intriguing. Either Tbx6 compensates for Msgn1 knockdown, or 4647 can induce uncommitted, non-PSM progenitor cells to differentiate into somitomeres.

**Relief of RARγ repression suppresses PSM and CNH marker gene expression**

If RARγ2 functions solely as a repressor, then RARγ2 knockdown should induce a loss of repression phenotype. RARγ2 MO microinjection resulted in severely truncated body axes with caudal PSM and posterior Hox markers significantly reduced at tailbud stages, similar to 4647 treatment. This phenotype was attributed to axial defects, not merely developmental delay. We noted three differences between 4647-treated and RARγ2 MO-injected embryos. First, axes of RARγ2 MO embryos were significantly curved, which was attributed to imbalance/dominance of the uninjected side versus the truncated injected side. Second, caudal PSM markers, while qualitatively reduced with RARγ2 MO, also expanded rostrally, even when accounting for shortened axes on injected sides. Third, thickened, posteriorly expanded somitomeres were not seen with RARγ2 MO, or (B) 5 ng RARγ2 MO+5 ng RARγ2.2 MO diminishes Hoxc10 expression and curves the embryo axis. (C,D) 2 ng DN-RARγ2 mRNA partially rescues this effect and expands neural expression of Hoxc10. Tailbud embryos shown in dorsal view with anterior to left. (D) Detailed scoring of the rescue experiment.

**Morphology**

![Morphology](image-url)
RARγ functions as both transcriptional activator and repressor during somitogenesis and axial elongation. RARγ is activated by RA near the determination wavefront where PSM differentiates into somitomeres, then mature somites. The progenitor pool within the PSM and CNH domains, which is maintained by RARγ repression, feeds into the wavefront until exhausted, as somitogenesis proceeds faster than progenitors are replenished (Gomez and Pourquier, 2009). As PSM and CNH domains diminish, the distance between RA/wavefront (blue line) and the posterior tip of the embryo (green line) becomes shorter. RA is able to enter the posterior, activating RARγ, switching its function from repressor promoting growth to activator terminating growth. RXR, retinoid X receptor.

Fig. 10. RARγ functions as both transcriptional activator and repressor during somitogenesis and axial elongation. RARγ is activated by RA near the determination wavefront where PSM differentiates into somitomeres, then mature somites. The progenitor pool within the PSM and CNH domains, which is maintained by RARγ repression, feeds into the wavefront until exhausted, as somitogenesis proceeds faster than progenitors are replenished (Gomez and Pourquier, 2009). As PSM and CNH domains diminish, the distance between RA/wavefront (blue line) and the posterior tip of the embryo (green line) becomes shorter. RA is able to enter the posterior, activating RARγ, switching its function from repressor promoting growth to activator terminating growth. RXR, retinoid X receptor.

2013). Hoxc10 expression could be rescued in Raryγ MO-injected embryos by co-injecting DN-Raryγ mRNA, definitively establishing that RARγ2 functions as a repressor in the caudal domain. DN-Raryγ2 restored Hoxc10 expression, especially in neural tube, where additional expansion was often observed. DN-Raryγ2 rescue restored curved axes only partially. We predict that axial curvature is a loss-of-activation effect inhibiting somitomere formation; therefore, the phenotype should not be rescued by DN-RARγ2, but rescued by wild-type RARγ2, as we observed.

Perhaps the most direct method for relieving repression of RARγ2 in caudal regions is overexpression of dominant-negative co-repressor c-SMRT, which binds RARγ2 preventing recruitment of co-repressors and thereby blocking repression. c-SMRT overexpression resulted in truncated axes with loss of posterior Hox, unsegmented PSM and CNH markers, but no rostral shifting of Megn1 and Tbx6 as had been observed for Raryγ MO embryos. This indicates that rostral shifting in Raryγ MO embryos results from loss of activation rather than relief of repression. We previously showed that c-SMRT not only relieves repression of RAR but also potentiates ligand-mediated activation (Koide et al., 2001). Since c-SMRT was expressed ubiquitously, it could superactivate RARα or RARγ where RA is present. It should also be noted that c-SMRT can interact with other nuclear receptors and transcription factors. Therefore, we can only conclude that c-SMRT overexpression inhibits maintenance of the caudal PSM and progenitor pool (where RA is absent). We cannot draw conclusions about somitomere markers in c-SMRT overexpression embryos since their expression is controlled by RAR activation, which c-SMRT does not reduce.

RAR signaling and posterior Hox gene regulation
We identified a novel function for RARγ as a transcriptional repressor in the regulation of posterior Hox genes. Posterior Hox genes pattern caudal embryonic regions, promote axial elongation (Young et al., 2009) and are linked to cell cycle progression (Gabellini et al., 2003) and therefore proliferation. Axial elongation involves the addition of tissue, as cells must proliferate to contribute segments. Normally, FGF and RA signaling are mutually antagonistic, but we provide evidence that RARγ can support proliferative mechanisms in the absence of RA.

Hox gene expression was altered by 4647 and 5099 treatment, even post-gastrulation. Hence, although Hox gene expression is initiated collinearly during gastrulation, this temporal pattern is not immutable. In support of this model, axial progenitor cells transplanted to anterior locations do not retain their previous Hox identity (McGrew et al., 2008). Furthermore, manipulation of anteroposterior locations of PSM and the determination wavefront resulted in corresponding changes in Hox gene expression (Limura et al., 2009; Wellik, 2007). We showed that 4647 treatment pushes determination fronts caudally and observed posterior regressions of Hoxc10, Hoxd10 and Hoxc13 expression. Conversely, rostral expansion in PSM by increasing RAR repression was accompanied by anterior shifts in posterior Hox expression. Owing to posterior prevalence, rostral shifts of Hoxc10 or Hoxd10 expression could indicate that thoracic segments will develop caudal structures at later stages. Similarly, rostral shifts in Hoxc13 could drive lumbar segments to sacral morphology. Homeotic transformations from manipulating RAR repression deserve future study.

Conclusions
We conclude that the RAR-mediated repression of caudal genes is crucial for axial elongation, establishing another important role for active repression by nuclear receptors in body axis extension, as previously shown for head formation (Koide et al., 2001). RARγ2 is likely to function as an activator near the determination wavefront and a repressor to maintain axial progenitor pools in the PSM and CNH. As axial elongation nears completion, RARγ2 functions as an activator because the progenitor pool is exhausted and RA comes into close proximity to the caudal domain of RARγ2, where it can then promote apoptosis and terminate the body axis. This model is attractive because it utilizes the same protein to activate or repress target genes depending on the proximity to RA and explains the high levels of posterior RARγ2 expression. RARγ2 is likely to function in multiple steps of somitogenesis and axial elongation (Fig. 10): (1) preservation of undifferentiated states in the progenitor pools (marked by the CNH); (2) maintenance of PSM; (3) initiation of somitomere differentiation; and (4) axial termination. Future studies require RARγ target gene identification because very few ChIP studies have ascertained direct targets, and even fewer studies have explored subtype-selective RAR targets. In the case of inverse agonist-upregulated genes (the focal point of our study), identifying repressors of PSM and progenitors will be key, as these genes are likely to be targeted by unliganded RAR in a classic ‘repression of a repressor’ mechanism.

MATERIALS AND METHODS
Perceollome microarray analysis
Xenopus laevis eggs from three different females were fertilized in vitro and embryos staged as described (Janiesick et al., 2012). Stage 7 embryos were treated in groups of 25 in 60-mm Petri dishes with 10 ml 0.1× MBS containing 1 μM RAR agonist (TTNPB), 1 μM RAR inverse agonist (AGN193109) or vehicle control (0.1% ethanol). Three dishes per treatment per female were exposed to treatments for 4 h. Each dish of embryos was harvested at stage 18 into 1.5 ml RNAlater (Invitrogen) and stored at 4°C. Samples were homogenized, RNA isolated and DNA quantitated (Kanno et al., 2006). Graded-dose spiked cocktail
(GSC) made of five Bacillus subtilis RNA sequences present on Affymetrix GeneChip arrays (AffX-ThrX-3_at, AffX-LysX-3_at, AffX-PheX-3_at, AffX-DapX-3_at, AffX-TrpX-3_at) was added to the sample homogenates in proportion to their DNA concentration (Kanno et al., 2006). GSC-spiked sample homogenates were processed and probes synthesized using standard Affymetrix protocols, applied to Xenopus microarray v1.0 GeneChips and analyzed using Percollome software (Kanno et al., 2006). Absolutized mRNA levels were expressed as copy number per cell for each probe set.

Percollome microarray data were analyzed using CyberT (Kayala and Baldi, 2012). We did not use low value thresholding/offsetting or log/VSN normalizations. Bayesian analysis used a sliding window of 101 and confidence value of 10. The P-values reported are Bonferroni corrected and Benjamini and Hochber corrected. The full microarray dataset is available at GEO under accession number GSE57352. Genes included in Table 1 comprised a subset upregulated by AGN193109 downregulated by TTPNB based on their regional expression in the posterior.

**Embryo microinjection**

Xenopus eggs were fertilized in vitro and embryos staged as described (Janiesick et al., 2012). Embryos were injected bilaterally or unilaterally at the 2- or 4-cell stage with gene-specific morpholinos (MOs) (supplementary material Table S1) and/or mRNA together with 100 pg/embryo β-galactosidase (β-gal) mRNA. For all MO experiments, control embryos were injected with 10 ng standard control MO (GeneTools). Embryos were maintained in 0.1 × MBS until appropriate stages. Embryos processed for WISH were fixed in MEMFA, stained with magenta-GAL (Biosynth), and then stored in 100% ethanol (Janiesick et al., 2012).

pCDG1-DN-xRary2 was constructed by cloning amino acids 1-393 (lacking the AF-2 domain) into the Ncol-BamHI site of pCDG1 (Blumberg et al., 1998). pCDG1-VP16-xRary2 was cloned by cloning the VP16 activation domain upstream of xRary2 into pCDG1. pCDG1-xRary2, pCMX-GAL4-Rara and GAL4-Rary were from Blumberg et al. (Blumberg et al., 1996). X. laevis Rarβ and Rarβ2 sequences were found by aligning to the X. tropicalis sequences. pCDG1-xRarβ2 and pCMX-GAL4-xRarβ cloning primers are listed in supplementary material Table S2. pCDG1-xCyp26a1 and pCDG1-c-smr were constructed by PCR amplification of xCyp26a1 coding regions (Hollemann et al., 1998) or Xc-smr (37b−, 41+) (Chen et al., 1996; Malarte et al., 2004) and cloning into pCDG1.

**Transfection**

The effector plasmid was co-transfected with 5 µg tk-(RXRE1/2-GRE1/2)+4 luciferase reporter and 5 µg pCMX-β-galactosidase transfection control plasmids as previously described (Chamorro-Garcia et al., 2012). For activation assays, NRX204647 was tested from 10^{-11} M to 10^{-5} M. For antagonism assays, NRX205099 was tested from 10^{-10} M to 10^{-6} M against 10^{-8} M 9-cis RA. All transfections were performed in triplicate and reproduced in multiple experiments. Data are reported as normalized luciferase ± s.e.m. or percentage reduction ± s.e.m. using standard propagation of error (Bevington and Robinson, 2003).

**Quantitative real-time reverse transcription PCR (QPCR)**

Total RNA from five-embryo pools was DNase treated, LiCl precipitated, and reverse transcribed into cDNA (Janiesick et al., 2012). First-strand cDNA was quantitated in a Light Cycler 480 System (Roche) using primer sets listed in supplementary material Table S5 and SYBR Green. Each primer set amplified a single band as determined by gel electrophoresis and melting curve analysis. QPCR data for supplementary material Figs S2 and S7 were analyzed by ANOVA relative to Histone H4, correcting for amplification efficiency between RARs (Pfaffl, 2001). QPCR data for supplementary material Figs S11 and S12 were analyzed by ANOVA relative to Histone H4, normalizing to control embryos. Error bars represent biological replicates calculated using standard propagation of error.

**Acknowledgements**

We thank Connie Chung for technical help during the early stages of this study and Dr Dennis Bittner for editorial assistance.

**Competing interests**

The authors declare no competing financial interests.

**Author contributions**

T.L.N. performed WISH. K.A., K.I., S.K. and J.K. executed the Percollome microarray experiment. R.A.S.C. provided 4647 and 5099 chemicals with advice on use. A.J. and B.B. designed, supervised and performed experiments, and wrote, edited and submitted the manuscript.

**Funding**

Supported by grants from the National Science Foundation (NSF) [IOS-0719576, IOS-1147236 to B.B.]. A.J. was a predoctoral trainee of NSF IGERT DGE 0549479. K.I., S.K. and J.K. were funded by Health Sciences Research Grant H15-kagaku-002 from the Ministry of Health, Labour and Welfare, Japan.

**Supplementary material**

Supplementary material available online at http://dev.biologists.org/lookup/suppl/doi:10.1242/dev.103705/-/DC1

**References**


Supplemental Figure S1. Xenopus laevis RARs repress basal transcriptional activity. (A, B) Cos7 cells were transfected with 5:5:1 DNA ratio of reporter : β-gal : Gal4-RAR (or Gal4 alone), and treated with 10 μM 9-cis RA or vehicle (0.1% DMSO). The y-axes represent relative light units measured by the luminometer normalized to β-gal activity (A, B) or embryo number (C). Basal reporter activity (A, B-gray bars, D) is repressed by xRARα (A-blue bar, E), hRARα (B-blue bar, E), xRARβ (A-green bar, E), and xRARγ (A-red bar, E), but not repressed by hRARβ (B-green bar), or hRARγ (B-red bar). (A, B, F) RA activates xRARs and hRARs. (C) Embryos were injected unilaterally at the 2- or 4-cell stage with 50 pg reporter DNA and 50 pg Gal4-xRAR mRNA then treated at stage 9 with 1 μM 9-cis RA or vehicle (0.1% EtOH). Basal reporter activity (C-gray bar, D) is repressed by xRARα (C-blue bar, E), xRARβ (C-green bar, E), and xRARγ (C-red bar, E). (C, F) RA relieves repression and activates xRARs. Statistical significance was determined using unpaired t-test in GraphPad Prism v5.0. Asterisks represent statistical significance compared to reporter alone (** P ≤ 0.001).
Supplemental Figure S2. Expression of Rarγ1 and Rarγ2. (A) WISH of Rarγ1 and Rarγ2 mRNA expression at stages 19, 22, and 30. Dorsal (D) and lateral (L) views are shown with anterior to the left. (B) QPCR showing developmental expression of Rarγ1 and Rarγ2 mRNAs. The y-axis represents 2^{-ΔCt} values (adjusted for primer efficiency), normalized to reference gene, Histone H4.
Supplemental Figure S3. Double WISH Reveals Spatial Relationship between \textit{Rar\gamma 2} and presomitic mesoderm genes at the tailbud stage. (A-H) \textit{Rar\gamma 2} is stained with BM Purple and presomitic mesoderm genes are stained with Fast Red. \textit{Rar\gamma 2} is caudal to \textit{Tbx6} (A, B), but is synexpressed with \textit{Msgn1} (C, D). \textit{Rar\gamma 2} overlaps with S-III domains of \textit{Ripply2} (E, F) and \textit{Thyl2} (G, H), but not with more anterior somitomeres (S-II, S-I, S0). Dorsal and lateral views are shown with anterior to the left.
Supplemental Figure S4. Double WISH Reveals Spatial Relationship between *Raldh2* and *Thyl2*. (A) *Raldh2* overlaps all somitomere domains (S-III, S-II, S-I) of *Thyl2*. (B) Graphical representation of (A). Lateral views are shown with anterior to the left.
Supplemental Figure S5. Late-stage phenotypes of RARγ-selective chemicals 4647 and 5099. (A) Embryos treated post-gastrulation (stage 12.5) with 1 μM-10 nM 4647, or 1 μM-0.1 μM 5099, or vehicle (0.1% EtOH). (B) Embryos treated at neurula stage 16 with 1 μM - 50 nM 4647, or 1 μM 5099, or vehicle (0.1% EtOH). Embryos are shown in lateral view at stage 40; anterior is on the left.
Supplemental Figure S6A. hRARγ-selective chemical 4647 is selective on xRARγ. (Top) Cos7 cells were transfected with 5:5:1 DNA ratio of reporter: β-gal: xRAR EGCKG→GSCKV (or mCherry control), and treated with 10 μM-10 fM 4647 or vehicle (0.1% DMSO). The y-axis is the relative light units measured by the luminometer divided by β-gal activity. The region of xRARγ-selectivity is the concentration of 4647 that activates xRARγ1 and xRARγ2 but fails to activate xRARα1 and RARα2. (Bottom) Schematic of the full-length mutant RAR EGCKG→GSCKV system using the (RXRE^{1/2}-GRE^{1/2})x4 TK-Luciferase reporter.
Supplemental Figure S6B. hRARγ-selective chemical 5099 is selective on xRARγ. (Top) Cos7 cells were transfected with 5:5:1 DNA ratio of reporter : β-gal : xRAREGCKG→GSCKV (or mCherry control), and treated with 10 μM-0.1 nM 5099 or vehicle (0.1% DMSO) against 10 nM 9-cis RA. The y-axis is % reduction (100% = 9-cis RA alone) of relative light units divided by β-gal activity. The region of xRARγ-selectivity is the concentration of 5099 that represses xRARγ1 and xRARγ2 but fails to repress xRARα1 and RARα2. (Bottom) Schematic of the full-length mutant RAREGCKG→GSCKV using the (RXRE\textsuperscript{1/2}-GRE\textsuperscript{1/2})\textsubscript{4} TK-Luciferase reporter.
Supplemental Figure S7. Expression of *Hoxc13* across developmental time. WISH of *Hoxc13* mRNA expression at developmental stages 16 (A, B), 22 (C, D), and 30 (E, F). Dorsal (A, C, F) and lateral (E) views are shown with anterior to the left. Caudal (B, D) views are shown with dorsal at the top. (G) QPCR showing developmental expression of *Hoxc13*. The y-axis represents $2^{-\Delta Ct}$ values, normalized to reference gene, *Histone H4*.
Supplemental Figure S8. Pulse treatments determine short-term effects of 4647 and 5099. WISH from embryos treated for one hour at stage 12.5, 14, 16, 18, and 22 with 10 nM 4647, 0.5 μM 5099, or vehicle (0.1% EtOH). (A) Quantitation of purple pixels with respect to total embryo body pixels. (B) Quantitation of Hoxc10 neural stain length with respect to total body axis length. Statistical significance was determined using 1-way ANOVA in GraphPad Prism v5.0. (* = P ≤ 0.05, *** = P ≤ 0.001). (C) Representative embryos from this experiment. Embryos shown in dorsal view at tailbud-stage; anterior on left. Dashed red line represents 1/2 the embryo axis.
Supplemental Figure S9. Hoxc10, Krox20, and En2 expression domains are reduced by 4647 and expanded by non-receptor-selective doses of 5099. (A-H) WISH from embryos treated post-gastrulation (stage 12.5) with non-receptor-selective doses of 4647, 5099, or vehicle (0.1% EtOH). (A, B) Control expression of Hoxc10, hindbrain marker Krox20, and midbrain marker En2. (C-F) 0.1 μM 4647 diminishes (14/14), and 1 μM knocks out (15/15), expression of Hoxc10. 0.1 μM and 1 μM doses obliterate Krox20 and En2 (0.1: 14/14; 1: 15/15). (G, H) 1 μM 5099 rostrally expands expression of Hoxc10 and caudally expands Krox20, and En2 (14/15). Embryos are shown in lateral or dorsal view at tailbud-stage; anterior is on the left.
Supplemental Figure S10. Presomitic mesoderm markers are significantly altered by 4647 and 5099. (A-R) WISH from embryos treated post-gastrulation (stage 12.5) with non-receptor-selective doses of 4647, 5099, or vehicle (0.1% EtOH). (A-D) Control expression of Msgn1, Tbx6, Thyl2 and Ripply2. (E) Msgn1 expression is diminished by 4647 (15/15 embryos). (F) Tbx6 expression is expanded by 4647 (17/17). (G, H) Somitomere domains of Thyl2 (20/20) and Ripply2 (21/21) are thicker, posteriorly expanded, and lack lateral expression. Anterior, ectopic somitomeres are visible in 60% of embryos. (I, J) Msgn1 (15/15) and Tbx6 (17/17) expression are expanded with 5099. (K, L) Somitomere domains of Thyl2 (18/18) and Ripply2 (17/17) are reduced in number and thinner. Embryos are shown in dorsal view at neurula-stage; anterior is on the left. (M-R) Caudal views of Msgn1, and Tbx6.
Supplemental Figure S11. Rary2 is not inducible by TTNPB. PCR showing xRara1, xRara2, and xRary2 expression in embryos treated at stage 7/8 with 1 μM TTNPB or vehicle (0.1% EtOH). The y-axis represents $2^{-\Delta\Delta C_t}$ values normalized to Histone H4 and expressed as fold induction relative to control. xRara2 is induced by TTNPB whereas xRary2 is repressed by TTNPB. Statistical significance was determined using unpaired t-test in GraphPad Prism v5.0 (* = P ≤ 0.05, ** = P ≤ 0.01).
Supplemental Figure S12. *Rarγ2* splice MO significantly reduces *Rarγ2* expression. (A) QPCR of cDNA of uninjected embryos or embryos bilaterally injected with *Rarγ2* splice MO. The y-axis represents $2^\Delta\Delta CT$ values normalized to *Histone H4* and expressed as fold reduction relative to control. 20 ng and 40 ng of *Rarγ2* splice MO yielded significant reduction of *Rarγ2* expression. Statistical significance was determined using unpaired t-test in GraphPad Prism v5.0 (** P ≤ 0.001). Primer sequences are found in Table S6. (B, C) Embryos were injected unilaterally at the 2- or 4-cell stage with 40 ng *Rarγ2* splice MO. The injected side is indicated by the magenta β-gal lineage tracer. *Rarγ2* splice MO resulted in curved axes on the injected side, and decreased expression of *Hoxc10* (14/14 neural KD, 8/14 lateral KD, 6/14 lateral blurring) and *Hoxd10* (26/26 KD/KO).
Supplemental Figure S13. Embryos were injected bilaterally at the 2-cell stage with 5 ng Rarγ MO or Control MO. Control MO did not alter expression of (A) MyoD, (B) Otx2, Krox20, and Hoxc10, and (C) Otx2, Krox20, and Msgn1 in stage-33 embryos. Rarγ 1/2.2 MO resulted in blurred and reduced somite domains (E), and diminished head and tail patterning (F, G) in stage-33 embryos. Embryos are shown in dorsal and lateral views with anterior on the left. (D, H) Unbleached, unstained embryos.
Supplemental Figure S14. c-SMRT relieves repression of xRARγ2. (A) Embryos were injected unilaterally at the 2- or 4-cell stage with 50 pg reporter DNA, and 50 pg Gal4-xRarγ2 mRNA +/- 4 ng c-smrt mRNA then treated at stage 9 with 1 μM TTNPB or vehicle (0.1% EtOH). Basal reporter activity (A, B) is repressed by xRARγ2 (A, C). (A, D) c-SMRT relieves repression of xRARγ2, and this effect is potentiated by TTNPB. Statistical significance was determined using unpaired t-test in GraphPad Prism v5.0 (* = P ≤ 0.05, ** = P ≤ 0.01, *** = P ≤ 0.001).
Supplemental Figure S15. *Cyp26a1* mRNA overexpression expands posterior Hox gene expression domains. Embryos were injected unilaterally at the 2- or 4-cell stage with 1 ng *Cyp26a1* mRNA. The injected side is indicated by the magenta β-gal lineage tracer. (A, B) *Cyp26a1* mRNA overexpression resulted in rostral shifting (green lines) of the neural/midline and/or lateral domains of *Hoxc10* (12/12 embryos) and *Hoxd10* (10/11) expression. Embryos are shown in at tailbud-stage with anterior on the left.
### Supplemental Table 1. Morpholinos

<table>
<thead>
<tr>
<th>MO</th>
<th>Type</th>
<th>Sequence (5'→3')</th>
</tr>
</thead>
<tbody>
<tr>
<td>Rarγ1</td>
<td>AUG</td>
<td>GCT GTT TGC CAT TGC CTT GTT CTA</td>
</tr>
<tr>
<td>Rarγ2</td>
<td>AUG</td>
<td>TTC CAT GCA GTC ATA CAT TTT GGG</td>
</tr>
<tr>
<td>Rarγ</td>
<td>Splice</td>
<td>GGG TAA CAC TTA CCT TGC AAC CTT C</td>
</tr>
</tbody>
</table>
Supplemental Table 2. xRARβ cloning primers

<table>
<thead>
<tr>
<th>Primer</th>
<th>pCMX-GAL4-xRARβ Sequence (5'→3')</th>
<th>pCDG1-xRARβ Sequence (5'→3')</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Forward</strong></td>
<td>TCG CCG GAA TTC TCC AAA GAA TCC GTC AGA AAT G</td>
<td>CAG ATA CCA TGG GAA TTG ACT GTA TGG ATG TTC TG</td>
</tr>
<tr>
<td><strong>Reverse</strong></td>
<td>TGG CCA GGA TCC TAT TGA ACC TGT GCA CAT TTA CTA AC</td>
<td>ACT AGT GGA TCC TAT TGA ACC TGT GCA CAT TTA CTA AC</td>
</tr>
</tbody>
</table>

PCR Template = *Xl* cDNA
### Supplemental Table 3. Two-Frag PCR of pCDG1-xRAR<sup>EGCKG→GSCKV</sup>

<table>
<thead>
<tr>
<th>Primer</th>
<th>xRARα&lt;sub&gt;1&lt;/sub&gt;&lt;sup&gt;EGCKG→GSCKV&lt;/sup&gt; or xRARα&lt;sub&gt;2&lt;/sub&gt;&lt;sup&gt;EGCKG→GSCKV&lt;/sup&gt; (5'→3')</th>
<th>xRARβ2&lt;sup&gt;EGCKG→GSCKV&lt;/sup&gt; (5'→3')</th>
<th>xRARγ1&lt;sup&gt;EGCKG→GSCKV&lt;/sup&gt; or xRARγ2&lt;sup&gt;EGCKG→GSCKV&lt;/sup&gt; (5'→3')</th>
</tr>
</thead>
<tbody>
<tr>
<td>A (α1)</td>
<td>CAG ATA CCA TGG CCA GTA AGG ACA A</td>
<td>CAG ATA CCA TGG GAA TGT TTG ACT GTA TGG ATG TTC TG</td>
<td>CAG ATA CCA TGG CAA ACA GCA GCA AG</td>
</tr>
<tr>
<td>A (α2)</td>
<td>CAG ATA CCA TGG TCA GTT TGG ATT TCA G</td>
<td>CAC CTT GCA ACT TCC ACA AGC GCT GAC TCC ATA GT</td>
<td>CAC CTT GCA ACT TCC ACA GAC TCC TCC AGG CGG AGT ATT CAG AA</td>
</tr>
<tr>
<td>B</td>
<td>CAC CTT GCA ACT TCC ACA AGC GCT GAC TCC ATA GT</td>
<td>CAC CTT GCA ACT TCC GCA TGA ACT GCC GCA ATG GTA ATG</td>
<td>CAC CTT GCA ACT TCC GCA TGA ACT GCC GCA ATG GTA ATG</td>
</tr>
<tr>
<td>C</td>
<td>CAC CTT GCA ACT TCC ACA AGC GCT GAC TCC TCC CGG CGG AGT ATT CAG AA</td>
<td>CAC CTT GCA ACT TCC ACA TGT TGG ACT GCC ATG GTG ATA</td>
<td>CAC CTT GCA ACT TCC ACA TGT TGG ACT GCC ATG GTG ATA</td>
</tr>
<tr>
<td>D</td>
<td>ACT AGT GGA TCC TCA GGG TGA GT</td>
<td>ACT AGT GGA TCC TAT TGA ACC TGT GCA CAT TTA CTA AC</td>
<td>ACT AGT GGA TCC TAT TGA ACC TGT GCA CAT TTA CTA AC</td>
</tr>
</tbody>
</table>

**PCR Template = pCDG1-xRARα<sub>1</sub> or pCDG1-xRARα<sub>2</sub>**

**PCR Template = Xl. cDNA**
Supplemental Table 4. Probes with T7 adapters

<table>
<thead>
<tr>
<th>Primer</th>
<th>Sequence (5'→3')</th>
</tr>
</thead>
<tbody>
<tr>
<td>F (xRARγ1)*</td>
<td>TTA CAG GAT CAC GTP AGA TTG AGC</td>
</tr>
<tr>
<td>R (xRARγ1)*</td>
<td>taa tac gac tca cta tag ggT GCT GCA CCC ATG GTT AAA GAC</td>
</tr>
<tr>
<td>F (xRARγ2)*</td>
<td>CTG TCT GCT ATC AGA GCC CAC</td>
</tr>
<tr>
<td>R (xRARγ2)*</td>
<td>taa tac gac tca cta tag ggT GTG GCT CTG CAT CCA TCC</td>
</tr>
<tr>
<td>F (Hoxc10)</td>
<td>CCA ACA ATG TGA CTC CTA ACT CGT</td>
</tr>
<tr>
<td>R (Hoxc10)</td>
<td>taa tac gac tca cta tag ggT CAG TTC CCG AAT TCG GTT CTC</td>
</tr>
<tr>
<td>F (Hoxd10)</td>
<td>TTT CTA TTC TAA CAG CGC CAG CA</td>
</tr>
<tr>
<td>R (Hoxd10)</td>
<td>taa tac gac tca cta tag ggC ACT CTT ACT GAT CTC TAG GCG G</td>
</tr>
<tr>
<td>F (Hoxa11)</td>
<td>TAA TCC CTC CAA TGT CTA CCA CCC</td>
</tr>
<tr>
<td>R (Hoxa11)</td>
<td>taa tac gac tca cta tag ggG TGG TGG CAG ATA TCC GTC TC</td>
</tr>
<tr>
<td>F (Hoxc13)</td>
<td>AAC TGT GCA AGC AGC CAC TG</td>
</tr>
<tr>
<td>R (Hoxc13)</td>
<td>taa tac gac tca cta tag gCT GCG GTA GTT CTC CTC</td>
</tr>
<tr>
<td>F (Ripply2)</td>
<td>GCA AGT GGT TTG CCA AGT CC</td>
</tr>
<tr>
<td>R (Ripply2)</td>
<td>taa tac gac tca cta tag ggC CAA ATC CAG AGT CTT CCT CC</td>
</tr>
<tr>
<td>F (Thylacine2)</td>
<td>ACA CTT AAA CCA GAG TCT TTC ACC T</td>
</tr>
<tr>
<td>R (Thylacine2)</td>
<td>taa tac gac tca cta tag ggA TCT GAA GCT TTG CCT TCA GTG G</td>
</tr>
<tr>
<td>F (Mesogenin)</td>
<td>AAT GGA AGA GGA CTA TGC CTT GAG</td>
</tr>
<tr>
<td>R (Mesogenin)</td>
<td>taa tac gac tca cta tag ggT CTT GGA GCA CTG GAG AAG GT</td>
</tr>
<tr>
<td>F (Tbx6)</td>
<td>GCC ACC TCC TAC ACG ATG AGA C</td>
</tr>
<tr>
<td>R (Tbx6)</td>
<td>taa tac gac tca cta tag ggC TCC TCT TCC TGG TCT CTA A</td>
</tr>
<tr>
<td>F (MyoD)</td>
<td>CAC TGC GGG ACA TGG AAG TC</td>
</tr>
<tr>
<td>R (MyoD)</td>
<td>taa tac gac tca cta tag ggG TAT TGC TGG GAG AAG GGG TGG T</td>
</tr>
<tr>
<td>F (Raldh2)</td>
<td>ACC CTT GAA TCT CTA AAC AGT GGC</td>
</tr>
<tr>
<td>R (Raldh2)</td>
<td>taa tac gac tca cta tag ggA ATC TCT TCT CTG GCA ATC CGC A</td>
</tr>
</tbody>
</table>

*Sense probes were PCR amplified from same primers except the T7-adapter was moved to the forward, 5' end.
# Supplemental Table 5. QPCR and PCR primers

## QPCR

<table>
<thead>
<tr>
<th>Primer</th>
<th>Sequence (5'→3')</th>
</tr>
</thead>
<tbody>
<tr>
<td>F (xRARα1)</td>
<td>CCA CAT ATG TTG GGG GGT ATG TC</td>
</tr>
<tr>
<td>R (xRARα1)</td>
<td>GAT TCT GGG GAG CGG TGG T</td>
</tr>
<tr>
<td>F (xRARα2)</td>
<td>CCA CTC AAT TGA GAC TCA GAG CAC</td>
</tr>
<tr>
<td>R (xRARα2)</td>
<td>CTC TTG TCC TGA CAC ACA AAG CA</td>
</tr>
<tr>
<td>F (xRARβ1)</td>
<td>TTT CCT CCT GTC ATT GGT GGA CTC</td>
</tr>
<tr>
<td>R (xRARβ1)</td>
<td>GCT CTG GGT TTC GAT GGT TGC</td>
</tr>
<tr>
<td>F (xRARβ2)</td>
<td>CAA ATG CTG GAT TTC TAC ACT GCG</td>
</tr>
<tr>
<td>R (xRARβ2)</td>
<td>GTG TTG CCA TCT TGT CTG TGC C</td>
</tr>
<tr>
<td>F (xRARγ1)</td>
<td>AGA ACA AGG CAA TGG CAA ACA G</td>
</tr>
<tr>
<td>R (xRARγ1)</td>
<td>GCA AGT ACT TCA AAT GGT GGA GAT C</td>
</tr>
<tr>
<td>F (xRARγ2)</td>
<td>GTA GAA ACA CAA AGT ACC AGC TCG</td>
</tr>
<tr>
<td>R (xRARγ2)</td>
<td>CCG TAG TGA TAA CCT GAA GAC TGG T</td>
</tr>
<tr>
<td>F (Hoxc13)</td>
<td>AAG GCT ACC AAC ACT GGG CTC</td>
</tr>
<tr>
<td>R (Hoxc13)</td>
<td>GAC CAC ATC TGG GAA AGG TGC</td>
</tr>
<tr>
<td>F (Histone H4)</td>
<td>GAT AAC ATC CAG GCC ATC AC</td>
</tr>
<tr>
<td>R (Histone H4)</td>
<td>TAA CCT CCG AAT CCG TAC AG</td>
</tr>
</tbody>
</table>

## PCR

<table>
<thead>
<tr>
<th>Primer</th>
<th>Sequence (5'→3')</th>
</tr>
</thead>
<tbody>
<tr>
<td>F (xRARγ2_Splice)</td>
<td>GCC GCT CTA TGA CAT GAG TCC</td>
</tr>
<tr>
<td>R (xRARγ2_Splice)</td>
<td>TTC CTC CGA GCT GGT ACT TTG TG</td>
</tr>
</tbody>
</table>